KG&L Capital Management’s Boston Scientific BSX Stock Holding History

KG&L Capital Management’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-4,170	Closed	-$407K	–	224
2025 Q3	$407K	Buy	4,170 +2,295	+122%	+$238K	0.11%	156
2025 Q2	$201K	Buy	+1,875	New	+$190K	0.06%	180

Other funds holding BSX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

KG&L Capital Management's BSX Position: Q4 2025 in Review

KG&L Capital Management sold out of Boston Scientific (BSX) in Q4 2025, closing a stake of 4,170 shares — an estimated $407K sold.

KG&L Capital Management first reported a position in BSX in Q2 2025 and held it in 2 quarters. The position peaked at $407K in Q3 2025. 1,783 funds tracked by Wall St. Rank hold BSX as of Q4 2025.

KG&L Capital Management reported no remaining Boston Scientific position as of Q4 2025 after selling out during the quarter.
KG&L Capital Management sold 4,170 Boston Scientific shares in Q4 2025, an estimated $407K.
KG&L Capital Management first reported a position in Boston Scientific in Q2 2025 and held it in 2 quarters.
KG&L Capital Management's Boston Scientific position peaked at $407K in Q3 2025.
1,783 funds tracked by Wall St. Rank held Boston Scientific as of Q4 2025.

Based on KG&L Capital Management's 13F filing for Q4 2025, filed 23 Jan 2026.